28 research outputs found
Association of Genetic Variants and Incident Coronary Heart Disease in Multiethnic Cohorts: The PAGE Study
Genome wide association studies identified several single nucleotide polymorphisms (SNPs) associated with prevalent coronary heart disease (CHD) but less is known of associations with incident CHD. The association of thirteen published CHD SNPs was examined in five ancestry groups of four large US prospective cohorts
Measuring alcohol consumption for genomic meta-analyses of alcohol intake: opportunities and challenges
Whereas moderate drinking may have health benefits, excessive alcohol consumption causes many important acute and chronic diseases and is the third leading contributor to preventable death in the United States. Twin studies suggest that alcohol-consumption patterns are heritable (50%); however, multiple genetic variants of modest effect size are likely to contribute to this heritable variation. Genome-wide association studies provide a tool for discovering genetic loci that contribute to variations in alcohol consumption. Opportunities exist to identify susceptibility loci with modest effect by meta-analyzing together multiple studies. However, existing studies assessed many different aspects of alcohol use, such as typical compared with heavy drinking, and these different assessments can be difficult to reconcile. In addition, many studies lack the ability to distinguish between lifetime and recent abstention or to assess the pattern of drinking during the week, and a variety of such concerns surround the appropriateness of developing a common summary measure of alcohol intake. Combining such measures of alcohol intake can cause heterogeneity and exposure misclassification, cause a reduction in power, and affect the magnitude of genetic association signals. In this review, we discuss the challenges associated with harmonizing alcohol-consumption data from studies with widely different assessment instruments, with a particular focus on large-scale genetic studies
Recommended from our members
Genetic variants in sex hormone pathways and the risk of type 2 diabetes among African American, Hispanic American, and European American postmenopausal women in the US.
BACKGROUND: Sex hormones are implicated in the development of diabetes. However, whether genetic variations in sex hormone pathways (SHPs) contribute to the risk of type 2 diabetes mellitus (T2DM) remains to be determined. This study investigated associations between genetic variations in all candidate genes in SHPs and T2DM risk among a cohort of women participating in the Womens Health Initiative (WHI). METHODS: Single nucleotide polymorphisms (SNPs) located within 30âkb upstream and downstream of SHP genes were comprehensively examined in 8180 African American, 3498 Hispanic American, and 3147 European American women in the WHI. In addition, whether significant SNPs would be replicated in independent populations was examined. RESULTS: After adjusting for age, region, and ancestry estimates and correcting for multiple testing, seven SNPs were significantly associated with the risk of T2DM among Hispanic American women were identified in the progesterone receptor (PGR) gene, with rs948516 showing the greatest significance (odds ratio 0.67; 95% confidence interval 0.57-0.78; Pâ=â8.8âĂâ10-7 ; false discovery rate, Qâ=â7.8âĂâ10-4 ). These findings were not replicated in other ethnic groups in the WHI or in sex-combined analyses in replication studies. CONCLUSION: Significant signals were identified implicating the PGR gene in T2DM development in Hispanic American women in the WHI, which are consistent with genome-wide association studies findings linking PGR to glucose homeostasis. Nevertheless, the PGR SNPs-T2DM association was not statistically significant in other ethnic populations. Further studies, especially sex-specific analyses, are needed to confirm the findings and clarify the role of SHPs in T2DM
Reporting genetic results in research studies: Summary and recommendations of an NHLBI working group
Cilj rada je prikazati kontroling kao vaĆŸnu sastavnicu uspjeĆĄnosti na primjeru malih i srednjih poduzeÄa u Hrvatskoj. Prikazati Äe se pojmovno odreÄenje kontrolinga, sistematizacija koncepcija kontrolinga i odnos kontrolinga i drugih funkcionalnih podruÄja s kojima je kontroling povezan. Analizirati Äe se metode i tehnike analize poslovanja u konkretnom poduzeÄu ĆĄto Äe biti potkrijepljeno istraĆŸivanjem na temelju dostupnih primarnih i sekundarnih izvora informacija. U empirijskom dijelu rada analizirati Äe se zastupljenost kontrolinga u malim poduzeÄima u Hrvatskoj i uspjeĆĄnost provoÄenja kontrolinga
Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET)
Recommendations and guidance on how to handle the return of genetic results to patients have offered limited insight into how to approach incidental genetic findings in the context of clinical trials. This paper provides the Genomics and Randomized Trials Network (GARNET) recommendations on incidental genetic findings in the context of clinical trials, and discusses the ethical and practical issues considered in formulating our recommendations. There are arguments in support of as well as against returning incidental genetic findings in clinical trials. For instance, reporting incidental findings in clinical trials may improve the investigator-participant relationship and the satisfaction of participation, but it may also blur the line between clinical care and research. The issues of whether and how to return incidental genetic findings, including the costs of doing so, should be considered when developing clinical trial protocols. Once decided, plans related to sharing individual results from the aim(s) of the trial, as well as incidental findings, should be discussed explicitly in the consent form. Institutional Review Boards (IRBs) and other study-specific governing bodies should be part of the decision as to if, when, and how to return incidental findings, including when plans in this regard are being reconsidered
A Mechanism for Controlled Access to GWAS Data: Experience of the GAIN Data Access Committee
Confirmation of the Reported Association of Clonal Chromosomal Mosaicism with an Increased Risk of Incident Hematologic Cancer
<div><p>Chromosomal abnormalities provide clinical utility in the diagnosis and treatment of hematologic malignancies, and may be predictive of malignant transformation in individuals without apparent clinical presentation of a hematologic cancer. In an effort to confirm previous reports of an association between clonal mosaicism and incident hematologic cancer, we applied the anomDetectBAF algorithm to call chromosomal anomalies in genotype data from previously conducted Genome Wide Association Studies (GWAS). The genotypes were initially collected from DNA derived from peripheral blood of 12,176 participants in the Group Health electronic Medical Records and Genomics study (eMERGE) and the Womenâs Health Initiative (WHI). We detected clonal mosaicism in 169 individuals (1.4%) and large clonal mosaic events (>2 mb) in 117 (1.0%) individuals. Though only 9.5% of clonal mosaic carriers had an incident diagnosis of hematologic cancer (multiple myeloma, myelodysplastic syndrome, lymphoma, or leukemia), the carriers had a 5.5-fold increased risk (95% CI: 3.3â9.3; p-valueâ=â7.5Ă10<sup>â11</sup>) of developing these cancers subsequently. Carriers of large mosaic anomalies showed particularly pronounced risk of subsequent leukemia (HRâ=â19.2, 95% CI: 8.9â41.6; p-valueâ=â7.3Ă10<sup>â14</sup>). Thus we independently confirm the association between detectable clonal mosaicism and hematologic cancer found previously in two recent publications.</p> </div
Characteristics of mosaic anomalies.
<p>A) BAF and LRR metrics for mosaic anomalies by estimated copy change from disomic state (redâ=âloss, dark blueâ=âgain, orangeâ=âcopy neutral loss of heterozygosity. B) BAF and LRR metrics for mosaic anomalies by location (dark blueâ=âinterstitial, turquoiseâ=âp terminal, pinkâ=âq terminal or redâ=âwhole chromosome). C) BAF and LRR metrics for mosaic anomalies by type of chromosome (green circleâ=âacrocentric, purple crossâ=âmetacentric). D) BAF and LRR metrics for mosaic (red) and non-mosaic (black) anomalies.</p
Comparison characteristics of hematologic cancer cases and individuals without a diagnosed hematologic cancer during study follow-up.
<p>Comparison characteristics of hematologic cancer cases and individuals without a diagnosed hematologic cancer during study follow-up.</p